4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

10-Q - Vera Therapeutics, Inc. (0001831828) (Filer)

8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

424B5 - Vera Therapeutics, Inc. (0001831828) (Filer)

424B5 - Vera Therapeutics, Inc. (0001831828) (Filer)

8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

S-3ASR - Vera Therapeutics, Inc. (0001831828) (Filer)

144 - Vera Therapeutics, Inc. (0001831828) (Subject)

8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

144 - Vera Therapeutics, Inc. (0001831828) (Subject)

BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera's new Chief Legal Officer, under Vera's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option granted on November 18, 2024 has an exercise price

BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ

Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option granted on November 4, 2024 has an exercise price per share equal to $45.17, Vera's closing trading price on November 4

Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands the investigation of atacicept into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition; BRISBANE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, is partnering with the University of Michigan on the Nephrotic Syndrome Study Network (NEP

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1sWebcast: https://wsw.com/webcast/guggen/vera/1942294Date: Wednesday, November 13, 2024Time: 9:30am ESTLocation: Boston, MA 7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside Chat a

Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 with simultaneous peer-reviewed publication in the Journal of the American Society of Nephrology (JASN)Completed enrollment of the primary endpoint cohort in the pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN; topline data expected in Q2 2025Announced expanded atacicept development program in the broad IgAN population and in multiple autoimmune kidney diseasesCompleted an equity offering with gross proceeds of approximately $345 million ahead of potential regulatory submission

BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. ("Vera"), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A common stock at a price to the public of $42.00 per share. The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $300.0 million. In addition, Vera has granted the underwriters a 30-day option to purchase up to an additional 1,071,428 shar

BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. ("Vera"), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300.0 million of shares of its Class A common stock. All of the shares are being offered by Vera. In connection with the proposed offering, Vera expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering. There can be no assurance as to wheth

Long-term improvements observed in the quartet of findings defining disease modification supports atacicept's potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN Phase 2b study were simultaneously published in the Journal of the American Society of Nephrology;Company will host an investor call and webcast on Monday October 28 at 8:00 AM ET BRISBANE, Calif., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data from its ORIGIN Phase 2b trial of ataci

BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 125,000 shares of Class A common stock and restricted stock units (RSUs) for 62,500 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option granted on October 2, 2024 has an exercise price per share equal to $41.75, Vera's closing trading price on October 2,

Wells Fargo initiated coverage of Vera Therapeutics with a rating of Overweight and set a new price target of $70.00

Scotiabank initiated coverage of Vera Therapeutics with a rating of Sector Outperform

Oppenheimer initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $26.00

Cantor Fitzgerald initiated coverage of Vera Therapeutics with a rating of Overweight

Raymond James initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $29.00

Jefferies upgraded Vera Therapeutics from Hold to Buy and set a new price target of $26.00 from $18.00 previously

Guggenheim initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $27.00

Jefferies downgraded Vera Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously

Wedbush downgraded Vera Therapeutics from Outperform to Neutral and set a new price target of $8.00 from $33.00 previously

JP Morgan initiated coverage of Vera Therapeutics with a rating of Overweight and set a new price target of $35.00

BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ

BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to

BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the appointments of two industry veterans to help lead the development of the company's drug programs including its late-stage product candidate, atacicept, to treat autoimmune diseases, currently in a Phase 3 clinical trial for IgA nephropathy (IgAN). The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.; and William D. Turner as Chief Development Officer, effective immediately. "We

BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced the appointment of Kerry Cooper, M.D., to the role of Senior Vice President, Medical Affairs, where he will report to Chief Medical Officer Celia Lin and be responsible for overseeing medical affairs strategy and scientific communications. Dr. Cooper brings nearly 40 years of experience in nephrology across a variety of senior positions within industry, clinical practice and academia. He has led medical affairs strategies for drug de

Seasoned Commercial Operations Executive Positions Company for Next Stage of Growth Innocoll Holdings Ltd. ("IHL"), a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital ("GPC"), today announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer. As part of this appointment, Kimball will also serve as Chief Executive Officer of IHL's two subsidiaries: Syntacoll GmbH ("Syntacoll"), a contract development and manufacturing organization ("CDMO") specializing in collagen-based technology platforms, and Innocoll Biotherapeutics Inc. ("Innocoll"), a global biotech company focusing on delivering no

BRISBANE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, announced today the appointment Michael M. Morrissey, Ph.D., as chairman of its board of directors. Dr. Morrissey has served as president and chief executive officer (CEO) of Exelixis, Inc. since July 2010. "Mike's experience leading Exelixis' evolution into a fully integrated biopharmaceutical company will be immensely helpful to Vera as we prepare to move from late-stage clinical programs to potential commercial growth," said Kurt von Emster, Vera's cur

BRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Kimball Hall to its board of directors. Ms. Hall is a seasoned executive and a chemistry, manufacturing, and controls (CMC) expert. Formerly holding leadership positions at Genentech and Amgen, she is currently president and chief operating officer of Abzena, a biopharmaceutical focused contract development and manufacturing organization (CDMO). "We're honored to welcome Kimball to our board of directors," sai

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Sean Grant, MBA as Chief Financial Officer. In this role, he will oversee all of Vera Therapeutics' financial operations including financial strategy, investor relations, accounting operations, financial planning and analysis, tax, and treasury. Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, commented, "We are fortunate to have an executive with Sean's financial acumen and pedigree join

New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la

Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending cash runway to Q4 2024 Conference call and webcast to take place on January 30th at 8:00am ET BRISBANE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced results from a prespecified per-protocol (PP)

Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36 Atacicept safety profile in IgAN patients was similar to placebo Vera plans to advance atacicept into a pivotal Phase 3 trial in the first half of 2023 Company to host investor conference call and webcast on January 4, 2023, at 8:00 a.m. ET to further discuss results  BRISBANE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing

BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call at 8:00 a.m. ET on March 24, 2022. Title:Vera Therapeutics Business Update Call    Date:Thursday, March 24, 2022  Time:8:00 a.m. ET    Conference Call Details:Toll-Free: 1-877-423-9813International: 1-201-689-8573Conference ID: 13727899  Webcast:Webcast Link- Click Here The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusi

4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

3 - Vera Therapeutics, Inc. (0001831828) (Issuer)

4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

4 - Vera Therapeutics, Inc. (0001831828) (Issuer)